Longitudinal brain perfusion changes correlated with UPDRS Total in a Phase I mesenchymal stem cell trial for Parkinson’s disease
Objective: Explore changes in correlations between brain perfusion and UPDRS-Total (UPDRS-T) after a single infusion of allogeneic bone marrow-derived mesenchymal stem cells (MSC). Background: Our…Disease stage and nigrostriatal integrity predict motor progression in individuals with early Parkinson’s disease
Objective: To identify predictors of motor progression in individuals with early Parkinson’s disease (PD), who are either untreated or treated with monoamine oxidase B (MAO-B)…LRRK2 Inhibition by BIIB122 / DNL151: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Ph 1 Healthy Volunteer and Ph 1B Parkinson’s Disease Trials
Objective: To evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of the LRRK2 inhibitor, DNL151 (BIIB122), in healthy volunteers (HVs) and Parkinson’s disease (PD) patients. Background:…Cinpanemab in Early Parkinson’s Disease: Phase 2 SPARK Study Results
Objective: To evaluate cinpanemab (BIIB054) efficacy and safety. Background: Aggregated alpha-synuclein (α-syn), a major constituent of Lewy bodies, is thought to play a central role…Parkinson Progression Marker Initiative – New Science/New Cohorts
Objective: The Parkinson Progression Marker Initiative (PPMI) is expanding its cohorts and exploring additional biomarkers of PD progression to test hypotheses of the underlying molecular…Informing the design of disease modifying trials for Parkinson’s disease – A Delphi study
Objective: To assemble an international, multi-stakeholder Delphi panel to seek consensus on trial methodology for an adaptive trial platform investigating disease modifying therapies (DMTs) in…STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION
Objective: To evaluate whether long-term statin use may affect motor progression in a large cohort of de novo patients with Parkinson's Disease. Background: Statins are…Attitudes on therapy-associated risks in individuals with multiple system atrophy and Parkinson’s disease and their views on aspects of clinical trials
Objective: To assess risk attitudes of patients suffering from multiple system atrophy (MSA) and Parkinson’s disease (PD) on future disease-modifying therapies as well as related…Rapamycin attenuates nigral and hippocampal alpha-synuclein accumulation in AAV-mediated alpha-synuclein overexpression model of Parkinson’s disease
Objective: To examine the possible neurorestorative effects of chronic rapamycin treatment in AAV-mediated alpha-synuclein (a-syn) overexpression model of Parkinson’s disease (PD), designed to induce hippocampal…Fatty acids and Glucocerebrosidase activity as potential biomarkers of stearyl-CoA desaturase inhibition; an observational study of inter and intraday variation in healthy volunteers and patients with Parkinson’s disease
Objective: This study aimed to assess the naturally occurring levels and variation in plasma fatty acids (FA) and ceramide metabolism in healthy volunteers (HV) and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 16
- Next Page »